Anixa, OntoChem identify new anti-SARS-CoV-2 compounds

By The Science Advisory Board staff writers

August 13, 2020 -- Anixa Biosciences and OntoChem have identified 26 additional compounds that target the main protease inhibitors of SARS-CoV-2.

The companies will continue to evaluate the 26 compounds and expect to synthesize multiple candidates for further testing. Dr. Amit Kumar, president and CEO of Anixa, noted the compounds are so novel that the companies have begun drafting a U.S. patent.

Axia and OntoChem previously used in silico screening to identify four compounds that could disrupt the function of endoribonuclease (also known as nonstructural protein-15; NSP-15). They will continue performing biological testing on the initial four molecules going forward, according to Dr. Lutz Weber, CEO of OntoChem.

Anixa, OntoChem screen SARS-CoV-2 main protease inhibitors
Anixa Biosciences and OntoChem have completed in silico screening of four compounds that could function as SARS-CoV-2 main protease inhibitors.
Getting to the heart of SARS-CoV-2 protease; a main drug target
Getting to the heart of SARS-CoV-2 protease; a main drug target
Does SARS-CoV-2 use host defenses to infect susceptible cells?
A new study pinpoints the most likely cell types that SARS-CoV-2 infects. Unexpectedly, the study indicates that one of the body's main defenses against...
Scientists explore SARS-CoV-2 main protease as a drug target
A team of researchers report the structure of the main protease of the novel coronavirus and have identified several drugs that show promise in combating...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter